UNSPSC 51162344: Belladonna/chlorpheniramine/phenylephrine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

UNSPSC 51162344 Belladonna/chlorpheniramine/phenylephrine/phenylpropanolamine is a Commodity code that covers pharmaceutical products and over-the-counter medications purchased by state and local health agencies, counties, and cooperative purchasing alliances. The code encompasses generic multi-source pharmaceuticals and OTC products distributed to government health facilities, emergency response programs, and community health initiatives. Issuing bodies include county health departments, state cooperative purchasing alliances administering multi-jurisdictional pharmaceutical procurement, and specialized health agencies seeking to stock emergency medical supplies and community health inventories. These solicitations typically involve competitive bidding with volume requirements, wholesaler networks, and compliance certification including Good Manufacturing Practices and Drug Supply Chain Security Act adherence.

Recent activity spans Florida and Minnesota-led regional cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, with a response deadline of July 26, 2023 (original posting date appears inconsistent with current date; source shows June 30, 2026 posting with outdated due date). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026. The MMCAP RFP requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co.—and evaluates proposals primarily on price competitiveness (75 percent weighting) with secondary emphasis on fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Both solicitations require insurance coverage, E-Verify or manufacturing compliance certification, and contracts with initial two-year terms.